-
.
- Tonix Pharmaceuticals Holding Corp TNXP has actually gotten rid of the meantime evaluations in its registration-enabling, confirmatory Stage 3 durable research of TNX-102 SL for fibromyalgia as well as its Stage 2 avoidance research of TNX-1900 for persistent migraine headache.
- Meantime evaluations were anticipated in Q2 as well as Q4 of 2023, specifically.
- .
- Tonix Pharma Deprioritizes COVID-19 Related Programs, Pending PTSD Test .
- .
- .
- .
- TNXP shares are down 3.06% at $0.54 on the last check Thursday. .
.
.(* )The alterations to the RESILIENT as well as avoidance researches are created to improve the tests as well as to supply topline information for both programs in 2023.
Connected:
Target registration for the core TNX-102 SL fibromyalgia research continues to be at around 470 individuals, while target registration for the TNX-1900 persistent migraine headache research will certainly be decreased from around 300 individuals to around 150 individuals to fit the brand-new topline timing.
Topline outcomes are anticipated in the 4th quarter of 2023.
Topline outcomes of Stage 2 PREVAIL research of TNX-102 SL for fibromyalgia-type Lengthy COVID is anticipated in Q3 of 2023.
Cost Activity:
© 2023 Benzinga.com. Benzinga does not supply financial investment recommendations. All civil liberties scheduled.
